The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial

ConclusionsThese results suggest that after one year of denosumab, one year of alendronate is better able to maintain the inhibition of bone remodeling and BMD gains than raloxifene.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research